% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

  • fairandhonest2010 fairandhonest2010 May 7, 2013 1:49 PM Flag

    Rare long term growth potential...risk versus reward: tough batle

    This stock is truly interesting.

    It is moved so far so fast that going in is risky. No doubts.

    On the other hand, Eyelea had good sales, growth still there with expanding market, allergan drug delayed and other pipeline agents for growth.

    Tough battle in my mind.

    However, very few growth stocks so would go for it.

    Anyone has other point/counterpoint (not looking for short term play)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A balanced approach#$%$ are you doing on a message board? I would say there is slightly more reason to favor long term considerations. The unofficial position of the FDA is,if we don't outright reject it it will pass some day.Considering strong revenue streams from Eyelea,the delay is not significant. The intellectual portfolio of this company is quite strong. I would feel more comfortable if they split this sucker. You could always sell and hope the day-traders create some ghastly rumor and re-buy lower, Indeed a tough question,

508.51-10.27(-1.98%)Sep 3 4:00 PMEDT